WINNIPEG, Manitoba, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to announce that they have retained GR Consulting to develop and implement the out-licensing strategy for their DispersinB® wound care Hydrogel for both the United States and European markets.
“Gary and Edwin have years of experience and an exhaustive network in the wound care space that will allow Kane to not only accelerate the licensing of our technology, but also maximize the value of a future licensing agreement”, said Marc Edwards, Kane Biotech CEO.
“We’re excited to work with Kane Biotech on the future of DispersinB®. I believe that Kane’s strategy of using this enzyme to enhance the efficacy of products that are part of the current standard of care will prove very attractive to potential commercial partners”, said Gary Robinson, Principal of GR Consulting. "We’re looking forward to help shape the future of DispersinB®. Just the fact that peer-reviewed studies and reviews, from 2005 to 2019, mention it as a "thoroughly studied" "biofilm-dispersing" therapy, underlines its potential as a therapeutic approach that can help patients", said Dr. Edwin den Braber, Managing Partner at GR Consulting.
According to the USA National Institutes of Health (NIH), biofilms are estimated to be responsible for 80% of all human bacterial infections and are costly to deal with for consumers, industry, governments and hospitals. The DispersinB® enzyme is able to prevent and disperse many of these biofilms.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (56 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB(TM), DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE".
About GR Consulting
GR Consulting (GRc) is an international healthcare consultancy firm, providing strategic advisory services for healthcare and life science companies. GRc has a deep expertise in wound healing, biomaterials, implants, regenerative medicine and nanotechnology. Through an expansive network of subject and industry experts including R&D, commercial, clinical, regulatory, reimbursement, and financial disciplines GRc has successfully supported start-up and early stage companies to achieve and exceed their growth expectations.
For more information, please visit www.kanebiotech.com, or contact:
Marc Edwards
Chief Executive Officer
Kane Biotech Inc.
+1 (514) 910-6991 medwards@kanebiotech.com
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc.
+1 (204) 298-2200 rdupuis@kanebiotech.com
Joe Green
US. Investor Relations
Edison Inc.
+1 (646) 653-7030 jgreen@edisongroup.com
Laine Yonker
US. Investor Relations
Edison Inc.
+1 (646) 653 7035 lyonker@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
